JAMA Cardiology
Original Investigation
February 21, 2024
Michael T.ÌýLu, MD, MPH; Heather Ribaudo, PhD; Borek Foldyna, MD; Markella V.ÌýZanni, MD; Thomas Mayrhofer, PhD; Julia Karady, MD, PhD; Jana Taron, MD; Kathleen V.ÌýFitch, MSN; Sara McCallum, MPH; Tricia H.ÌýBurdo, PhD; Kayla Paradis, MBA; Sandeep S.ÌýHedgire, MD; Nandini M.ÌýMeyersohn, MD; Christopher DeFilippi, MD; Carlos D.ÌýMalvestutto, MD, MPH; Audra Sturniolo, MS; Marissa Diggs, BA; Sue Siminski, MBA; Gerald S.ÌýBloomfield, MD; Beverly Alston-Smith, MD; Patrice Desvigne-Nickens, MD; Edgar T.ÌýOverton, MD; Judith S.ÌýCurrier, MD; Judith A.ÌýAberg, MD; Carl J.ÌýFichtenbaum, MD; Udo Hoffmann, MD, MPH; Pamela S.ÌýDouglas, MD; Steven K.ÌýGrinspoon, MD; REPRIEVE Trial Writing Group
open access
has multimedia
JAMA Cardiol. 2024; 9(4):323-334. 10.1001/jamacardio.2023.5661
This substudy of a randomized clinical trial investigates the effects of pitavastatin on noncalcified coronary artery plaque using coronary computed tomography angiography and on inflammatory biomarkers as potential mechanisms for major adverse cardiovascular event prevention.
ÁñÁ«ÊÓƵ Network Open
Original Investigation
Infectious Diseases
April 26, 2023
Rachel A.ÌýBender Ignacio, MD, MPH; Kara W.ÌýChew, MD, MS; Carlee Moser, PhD; Judith S.ÌýCurrier, MD, MSc; Joseph J.ÌýEron, MD; Arzhang Cyrus Javan, MD, MPH, DTM&H; Mark J.ÌýGiganti, PhD; Evgenia Aga, MS; Michael Gibbs, PhD; Hervé Tchouakam Kouekam, MSc; Eva Johnsson, MD, PhD; Mark T.ÌýEsser, PhD, MBA; Keila Hoover, MD; Gene Neytman, DO; Matthew Newell, RN; Eric S.ÌýDaar, MD; William Fischer, MD; Courtney V.ÌýFletcher, PharmD; Jonathan Z.ÌýLi, MD, MMSc; Alexander L.ÌýGreninger, MD, PhD; Robert W.ÌýCoombs, MD, PhD; Michael D.ÌýHughes, PhD; Davey Smith, MD, MAS; David Alain Wohl, MD; Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV)–2/A5401 Study Team
open access
ÁñÁ«ÊÓƵ Netw Open. 2023; 6(4):e2310039. 10.1001/jamanetworkopen.2023.10039
These 2 phase 2 randomized clinical trials evaluated the safety and efficacy of single-dose combination tixagevimab and cilgavimab administered intramuscularly and intravenously, each compared with placebo, for treatment of symptomatic nonhospitalized adults with early COVID-19.
ÁñÁ«ÊÓƵ Network Open
Research Letter
Infectious Diseases
October 27, 2022
Davey M.ÌýSmith, MD, MAS; Jonathan Z.ÌýLi, MD; Carlee Moser, PhD; Eunice Yeh, MS; Judith S.ÌýCurrier, MD, MSc; Kara W.ÌýChew, MD, MS; Michael D.ÌýHughes, PhD; ACTIV-2/A5401 Study Team
open access
is active quiz
ÁñÁ«ÊÓƵ Netw Open. 2022; 5(10):e2238867. 10.1001/jamanetworkopen.2022.38867
This cohort study of US adults with untreated COVID-19 examines the types and length of symptoms experienced following symptom recurrence.
JAMA Internal Medicine
Original Investigation
March 14, 2005
Kathleen Mulligan, PhD; Robert Zackin, ScD; Rebecca A. Clark, MD, PhD; Beverly Alston-Smith, MD; Tun Liu, MS; Fred R. Sattler, MD; Thomas B. Delvers, RPh; Judith S. Currier, MD, MSc; AIDS Clinical Trials Group 329 Study Team and the National Institute of Allergy and Infectious Diseases Adult AIDS Clinical Trials Group
free access
Arch Intern Med. 2005; 165(5):578-585. 10.1001/archinte.165.5.578